Product Launch Details

Acrotech Biopharma Inc., a step-down subsidiary of Aurobindo Pharma Ltd., announced the U.S. launch of ADQUEY™ (difamilast 1%) ointment, a novel non-steroidal topical PDE4 inhibitor treatment for mild-to-moderate atopic dermatitis. The product is approved for adults and pediatric patients aged 2 years and older.

Market Context and Competition

The product enters a market estimated to be approximately US$ 1.3 billion for the twelve months ending July 2026, according to IQVIA MAT data. ADQUEY was originally discovered by Otsuka Pharmaceutical Co., Ltd. and licensed to Acrotech Biopharma for U.S. commercialization.

Strategic Business Expansion

The launch marks Acrotech's entry into the U.S. dermatology market and represents an expansion into a new strategic therapeutic area. The company has established a dedicated dermatology business unit with specialized commercial capabilities across marketing, sales, and field-based engagement to support this launch.

Business Unit Objectives

The dedicated dermatology division will focus on:

  • Building awareness of ADQUEY
  • Engaging with dermatology healthcare professionals
  • Supporting patients throughout their treatment journey
  • Developing infrastructure and expertise for future dermatology market expansion

Corporate Strategy Alignment

This launch builds on Acrotech's strategy to expand its portfolio of innovative medicines and establish focused commercial platforms in areas of significant patient need. The company describes this as establishing "more than a commercial organization around a single product" but rather creating "a dedicated dermatology platform designed to support ADQUEY today while creating the capabilities to pursue additional opportunities."

Corporate Structure Context

Acrotech Biopharma Inc. is identified as a step-down subsidiary of Aurobindo Pharma Ltd., India, formed as a global platform to commercialize innovative proprietary medications. The parent company, Aurobindo Pharma Limited, is described as an integrated global pharmaceutical company headquartered in Hyderabad, India, with operations in over 150 countries.

Management Commentary

Ashish Anvekar, President of Acrotech Biopharma, stated: "The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the U.S. dermatology market with a differentiated treatment option for patients living with atopic dermatitis. We are building more than a commercial organization around a single product. We are establishing a dedicated dermatology platform designed to support ADQUEY today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care."